Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kyowa Kirin Gains Rights to NHE3 Inhibitor in Japan
Kyowa Hakko Kirin said on November 28 that it has entered into a license agreement with Ardelyx for exclusive rights to develop and commercialize the US company’s NHE3 inhibitor tenapanor in Japan. Tenapanor, discovered by Ardelyx, is currently being developed…
To read the full story
Related Article
- Kyowa Kirin’s Phozevel Now Available for Hyperphosphatemia
February 20, 2024
- Kyowa Kirin Files Hyperphosphatemia Drug in Japan
October 31, 2022
- Tenapanor Hits Mark in Japan Hyperphosphatemia Study: Kyowa Kirin
December 14, 2021
- Kyowa Kirin Commences Japan PIII of NHE3 Inhibitor for Hyperphosphatemia
April 14, 2021
- Kyowa Kirin, Ardelyx Bolster Partnership with Additional Research Deal, US$20 Million Equity Investment
November 27, 2019
BUSINESS
- Halaven Generics Obtain Soft Tissue Sarcoma Use
September 3, 2026
- Ono Teams with Aitia in AI-Driven Neurology Drug Discovery
September 3, 2026
- Nippon Kayaku’s Generic Sunitinib Gains Pancreatic NET Use
September 3, 2026
- GSK Hit with MHLW Guidance over Sponsored Lecture
September 2, 2026
- Nonprescription Cialis Goes Nationwide in Japan, Now at 10,000 Outlets
September 2, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…